Back to Trades
Sell4
MADRIGAL PHARMACEUTICALS, INC.
MDGL
Total Value
$1.4M
Net $1.4M sold
Sales
$1.4M
1 transaction
Company Information
- Company Name
- MADRIGAL PHARMACEUTICALS, INC.
- Ticker Symbol
- MDGL
- CIK
- 0001157601
Insider Information
- Role
- President and CEO, Director
- Location
- WEST CONSHOHOCKEN, PA
DirectorOfficer
Filing Details
- Filing Date
- Dec 4, 2025
- Transaction Date
- Dec 3, 2025
- Accession Number
- 0001628280-25-055430
- Form Type
- 4
- Net Trading Amount
- -$1.4M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Dec 3, 2025 | Common Stock | 50,000 | — | Exercise | — |
| Dec 4, 2025 | Common Stock | 2,400 | $575.34 | Sale | $1.4M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Dec 3, 2025 | Derivative | 50,000 | — | Exercise | — |
Footnotes
- (F1)On December 3, 2025, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 3. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2028, the fifth anniversary of the commencement of his employment with the Issuer.
- (F2)The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.
- (F3)On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that can be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person can earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025 and the second hurdle reported on this line, the Reporting Person is eligible to earn an additional 50,000 shares upon the achievement of the final performance hurdle. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units.